Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference

Vistagen (NASDAQ:VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that company management

BusinesswireMay 7 08:30 ET

Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Acrivon Therapeutics, Inc. (ACRV)

TipRanksApr 27 08:10 ET

Express News | Vistagen Therapeutics Inc: Ph15 Was Safe and Well-Tolerated With an Adverse Event Profile Similar to Placebo

ReutersApr 25 08:30 ET

Express News | Vistagen Therapeutics Inc: Ph15 Nasal Spray Demonstrates Statistically Significant Efficacy Versus Placebo and Caffeine

ReutersApr 25 08:30 ET

Express News | Vistagen Announces Positive Results From Phase 2a Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

ReutersApr 25 08:30 ET

Vistagen Announces Positive Results From Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

Vistagen (Nasdaq: VTGN), a biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced positive results from a Phase 2A pilot study of PH15, an investigational pherine nasal spray, for improvement of psychomotor impairment caused by mental fatigue. PH15 demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants.

BusinesswireApr 25 08:30 ET